{
    "nctId": "NCT00017394",
    "briefTitle": "Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer",
    "officialTitle": "A Phase II Study of Bevacizumab in Combination With Vinorelbine in Stage IV Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 56,
    "primaryOutcomeMeasure": "Response rate to combination therapy with bevacizumab and vinorelbine, defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed stage IV breast cancer\n\n  * Patients without pathologic or cytologic confirmation of metastatic disease must have unequivocal evidence of metastasis by physical exam or radiologic study\n* Must meet 1 of the following criteria:\n\n  * Received 1 or 2 prior conventional chemotherapy regimens for metastatic disease\n  * Relapsed within 1 year after adjuvant chemotherapy and no prior chemotherapy for metastatic disease\n* At least 1 unidimensionally measurable lesion, meeting 1 of the following criteria:\n\n  * At least 20 mm by conventional techniques\n  * At least 10 mm by spiral CT scan\n* No CNS metastases by CT scan or MRI within the past 6 weeks\n* No prior or concurrent primary CNS tumor on physical exam\n* Disease progression after bone marrow or peripheral blood stem cell transplantation allowed\n* HER2-positive tumors allowed if previously treated with trastuzumab (Herceptin)\n* Hormone receptor status:\n\n  * Not specified\n* Male or female\n* Performance status - ECOG 0-2\n* Performance status - Karnofsky 60-100%\n* More than 3 months\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Hemoglobin at least 9 g/dL\n* Platelet count at least 100,000/mm\\^3\n* No prior bleeding diathesis or coagulopathy\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* AST/ALT no greater than 2.5 times ULN\n* INR no greater than 1.5\n* Creatinine less than 2 mg/dL\n* Urine protein no greater than +1 by dipstick\n* Urine protein less than 500 mg by 24-hour urine collection\n* LVEF at least 50%\n* No prior stroke\n* No New York Heart Association class II-IV congestive heart failure\n* No serious cardiac arrhythmia requiring medication, including atrial fibrillation requiring systemic anticoagulation\n* No grade II or greater peripheral vascular disease within the past year\n* No clinically significant peripheral artery disease\n* No deep vein thrombosis or embolism within the past 5 years\n* No arterial thromboembolic event within the past 6 months, including any of the following:\n\n  * Transient ischemic attack\n  * Cerebrovascular accident\n  * Unstable angina\n  * Myocardial infarction\n* No other significant cardiovascular disease\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No evidence of seizures not controlled with standard medical therapy\n* No prior allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or other agents used in the study\n* Prior mild infusion reaction to trastuzumab allowed\n* No serious non-healing wound, ulcer, or bone fracture\n* No significant traumatic injury within the past 4 weeks\n* No other concurrent illness (such as active infection) that would require active treatment or preclude study\n* No psychiatric illness or social situation that would preclude study\n* See Disease Characteristics\n* No prior bevacizumab\n* No other prior experimental angiogenesis inhibitors\n* At least 2 weeks since prior trastuzumab and recovered\n* Concurrent epoetin alfa or filgrastim (G-CSF) allowed\n* See Disease Characteristics\n* At least 2 weeks since prior chemotherapy and recovered\n* No prior vinorelbine\n* No more than 2 prior conventional chemotherapy regimens for metastatic breast cancer\n* Prior hormonal therapy allowed\n* At least 1 week since prior radiotherapy and recovered\n* No concurrent radiotherapy\n* At least 4 weeks since prior major surgical procedure or open biopsy\n* At least 1 week since prior fine-needle aspiration except in the breast\n* No concurrent major surgical procedure\n* Recovered from the toxic effects of any prior therapy\n* At least 10 days since prior oral or parenteral anticoagulants (e.g., heparin or warfarin) except to maintain the patency of permanent, indwelling central venous catheter\n* At least 10 days since prior thrombolytic agents\n* No chronic aspirin therapy greater than 325 mg per day or non-steroidal anti-inflammatory medications that inhibit platelet function\n* No concurrent COX-2 inhibitors that inhibit platelet function\n* No other concurrent investigational or commercial agents or therapies for the malignancy\n* No concurrent antiretroviral therapy for HIV-positive patients\n* No concurrent ketoconazole, zidovudine, or macrolide antibiotics\n* No concurrent oral or parenteral anticoagulants except to maintain patency of permanent, indwelling central venous catheter\n* No concurrent thrombolytic agent\n* Concurrent bisphosphonates allowed\n* Concurrent celecoxib or rofecoxib allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}